Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketorolac and Pregabalin in Primary Breast Cancer Patients
NCT06150898Phase 2Recruiting
- Sponsor
- Institut Jules Bordet
- Start
- May 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ketorolac and pregabalin in breast cancer (4 arms), sponsored by Institut Jules Bordet. Primary endpoints: Change in systemic inflammation, Change in systemic neurotransmitters and 7 more. Started May 2025; status: recruiting.
02
Drugs
ketorolacpregabalin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06150898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06150898.